

| PEDIATRICS All Fraser Health sites 2022 ANTIBIOGRAM (% Susceptible^a) | | GRAM POSITIVE | | | | | GRAM NEGATIVE | | | | This susceptibility chart is provided as a guide to empiric therapy until culture and susceptibility results are available. | |
|--|--|-----------------------|------|------|-----------------------|---------------------------------------|-----------------------|------------------|-----------------------|-------------------|---|------------------------|
| | | Staphylococcus aureus | MSSA | MRSA | Enterococcus faecalis | Streptococcus pneumoniae ^h | Group A Streptococcus | Escherichia coli | Klebsiella pneumoniae | Proteus mirabilis | | Haemophilus influenzae |
| Number of Isolates | | 516 | 421 | 95 | 102 | 23 | 54 | 826 | 44 | 47 | 112 | |
| Penicillins | Cloxacillin | 82 | 100 | R | | | | | | | | |
| | Penicillin | | | R | 99 | 88 [†] 100 [‡] | 100 | | | | | |
| | Ampicillin/Amoxicillin | | | R | 100 | 100 | 100 | 56 | R | 72 | 72 | |
| | Amoxicillin-Clavulanate | 82 | 100 | R | | | | 84 | 89 | 98 | | |
| | Piperacillin-Tazobactam | | | R | | | | 97 | 93 | 100 | | |
| Cephalosporins | Cephalexin ^b - 1st gen | 82 | 100 | R | R | | | 85 | 92 | 100 | | |
| | Cefazolin ^c - 1st gen | 82 | 100 | R | R | | 100 | 60 | 100 | 67 | | |
| | Cefuroxime - 2nd gen | | | R | R | 100 | | | | | | |
| | Cefixime - 3rd gen | | | R | R | | | 85 | 91 | 100 | | |
| | Cefotaxime / Ceftriaxone - 3rd gen | | | R | R | 100 | 100 | 88 | 95 | 100 | | |
| Ceftazidime - 3rd gen | | | R | R | | | 90 | 98 | 100 | | | |
| Carbapenems | Ertapenem - restricted | | | R | | | | 100 | 100 | 100 | | |
| | Imipenem - restricted | | | R | | | | | | | | |
| | Meropenem - restricted | | | R | | | | 100 | 100 | 100 | | |
| AMGs | Gentamicin | | | | | | | 92 | 98 | 94 | | |
| | Tobramycin | | | | | | | 93 | 100 | 98 | | |
| | Amikacin | | | | | | | 100 | 100 | 100 | | |
| FQs | Ciprofloxacin ^g | | | | 91 ^f | | | 71 | 91 | 89 | | |
| | Levofloxacin ^g | 77 | 86 | 37 | 92 ^f | 100 | | | | | | |
| | Moxifloxacin ^g | 77 | 86 | 37 | | 100 | | | | | | |
| Miscellaneous | Erythromycin ^d | 78 | 85 | 52 | R | 77 | 85 | | | | | |
| | Clindamycin | 86 | 87 | 82 | R | 96 | 85 | | | | | |
| | Tetracycline ^{e, g} | 96 | 98 | 88 | 18 ^f | 80 | | 79 | 91 | R | | |
| | Linezolid - restricted | 100 | 100 | 100 | 93 | | | | | | | |
| | Nitrofurantoin-simple cystitis only ^f | 94 | 93 | 100 | 100 | | | 99 | 24 | R | | |
| | TMP-SMX or Cotrimoxazole | 83 | 87 | 68 | R | 94 | | 79 | 93 | 85 | | |
| | Vancomycin | 100 | 100 | 100 | 100 | 100 | 100 | | | | | |
| Fosfomycin ^f | | | | | | | 100 | 86 | 98 | | | |

R = Intrinsically resistant

□ = Susceptibility not tested

NOTES:

- a. This antibiogram includes only the first isolate of a specific organism from any patient aged 17 and younger.
- b. Cephalexin susceptibility in gram-negatives is derived from urine isolates only and is predictive of ceftazolin susceptibility.
- c. Cefazolin susceptibility in gram-negatives is derived from nonurine isolates only and may underrepresent overall susceptibility.
- d. Organisms susceptible to erythromycin are also susceptible to azithromycin/clarithromycin.
- e. Organisms susceptible to tetracycline are also susceptible to doxycycline. However, some organisms that are nonsusceptible to tetracycline may be susceptible to doxycycline.
- f. From urinary tract isolates only.
- g. Use with caution in children
- h. Small number of isolates, interpret results with caution

[†] Data based on meningitis breakpoints

[‡] Data based on non-meningitis breakpoints

Developed by:
 Fraser Health Antimicrobial Stewardship Program, Department of Medical Microbiology, and Infection Prevention and Control